On 17 March 2020, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) stock observed trading -49.66% off 52-week high price. On the other end, the stock has been noted 15.17% away from low price over the last 52-weeks. The stock disclosed a move of -31.33% away from 50 day moving average and -26.08% away from 200 day moving average. Moving closer, we can see that shares have been trading -28.58% off 20-day moving average.
Ultragenyx Pharmaceutical Inc. (RARE) recently stated its financial results for the quarter and full year ended December 31, 2019 and reaffirmed its financial guidance for 2020.
Fourth Quarter and Full Year 2019 Financial Results
For the fourth quarter of 2019, Ultragenyx stated $35.6M in total revenue. Ultragenyx recognized $29.9M in total Crysvita revenue. This includes $26.1M in alliance revenue in the U.S. profit share territory and $2.2M in royalty revenue in the European territory from the alliance and license contract with Kyowa Kirin Co., Ltd (KKC). Net product sales for Crysvita in other regions were $1.6M. Mepsevii® (vestronidase alfa) product revenue for the fourth quarter of 2019 was $4.4M, and UX007 named patient revenue was $1.2M. Ultragenyx recognized $0.1M in revenue from its research contract with Bayer.
Net revenue for the year ended December 31, 2019 totaled $103.7M. In 2019, Ultragenyx recognized $87.3M in total Crysvita revenue. This includes $74.9M in alliance revenue in the U.S. profit share territory and $8.1M in royalty revenue in the European territory from the alliance and license contract with KKC. Net product sales for Crysvita in other regions totaled $4.3M. Mepsevii product revenue for the year ended December 31, 2019 was $12.6M, and UX007 named patient revenue was $3.3M. Ultragenyx recognized $0.5M in revenue from its research contract with Bayer in the year ended December 31, 2019.
Total operating expenses for the fourth quarter of 2019 were $130.0M contrast with $106.6M for the same period in 2018, including non-cash stock-based compensation of $19.7M and $21.1M in the fourth quarter of 2019 and 2018, respectively. Total operating expenses for the year ended December 31, 2019, were $527.9M, which includes $15.6M in expenditures for Arcturus alliance and license amendment and $20M for the upfront payment on the GeneTx contract, contrast with operating expenses of $422.9M for the same period in 2018. The operating expenses include non-cash stock-based compensation of $82.0M and $80.1M in the full year of 2019 and 2018, respectively. The increase in total operating expenses is Because of the increase in commercial, development, and general and administrative costs as the company commercializes, grows, and advances its pipeline.
For the fourth quarter of 2019, Ultragenyx stated a net loss of $93.8M, or $1.62 per share, basic and diluted, contrast with a net loss for the fourth quarter of 2018 of $87.8M, or $1.73 per share, basic and diluted. For the year ended December 31, 2019, the net loss was $402.7M, or $7.12 per share, basic and diluted, contrast with a net loss for the same period in 2018 of $197.6M, or $3.97 per share, basic and diluted. The loss for the fourth quarter of 2019 and for the year ended December 31, 2019 includes unrealized gains of $1.4M and $13.4M, respectively, from the fair value adjustments on the investment in Arcturus equity securities. The loss from the full year 2018 was reduced by the gain on the sale of the Mepsevii priority review voucher (PRV) in January 2018 for net proceeds of $130.0M and a $40.3M gain from Ultragenyx’s portion of the sales of the PRV received with the Crysvita authorization. The net loss for the full year 2019 reflected cash used in operations of $345.4M contrast to $290.6M for the same period in 2018.
Cash, Cash Equivalents and Investments
Cash, cash equivalents, and investments were $760.4M as of December 31, 2019, including proceeds of $320.0M received from the sale of the company’s royalty interest in Crysvita in the European territory.
The USA based company Ultragenyx Pharmaceutical Inc. moved with change of 10.95% to $37.5 with the total traded volume of 1102645 shares in recent session versus to an average volume of 559.49K. RARE’s shares are at -12.24% for the quarter and driving a -45.14% return over the course of the past year and is now at -12.20% since this point in 2018.
Mary Smith– Health Industry
My Name is Mary Smith, and I am 29 years old who is an industrialist other than a writer. I want to catch the attention of my audience and publishers without sounds too dry and dull. I am that sort of person who adores his spare time by writing my thoughts and ideas for my audience or readers. My writing skills are not confined to any specific field, I wrote on many topics, but healthcare sector and Stock Market articles are always my favorite. I love to express myself by creative modes such as drawing, singing, and writing. I love to spend my leisure time with my beloved cat, sleep or by playing my favorite video games.